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A B S T R A C T
Angiotensin II (AngII) elicits the production of superoxide (O2
•−) from mitochondria in numerous cell types
within peripheral organs and in the brain suggesting a role for mitochondrial-produced O2
•− in the pathogenesis
of hypertension. However, it remains unclear if mitochondrial O2
•− is causal in the development of AngII-
induced hypertension, or if mitochondrial O2
•− in the absence of elevated AngII is suﬃcient to increase blood
pressure. Further, the tissue speciﬁc (i.e. central versus peripheral) redox regulation of AngII hypertension
remains elusive. Herein, we hypothesized that increased mitochondrial O2
•− in the absence of pro-hypertensive
stimuli, such as AngII, elevates baseline systemic mean arterial pressure (MAP), and that AngII-mediated
hypertension is exacerbated in animals with increased mitochondrial O2
•− levels. To address this hypothesis, we
generated novel inducible knock-down mouse models of manganese superoxide dismutase (MnSOD), the O2
•−
scavenging antioxidant enzyme speciﬁcally localized to mitochondria, targeted to either the brain subfornical
organ (SFO) or peripheral tissues. Contrary to our hypothesis, knock-down of MnSOD either in the SFO or in
peripheral tissues was not suﬃcient to alter baseline systemic MAP. Interestingly, when mice were challenged
with chronic, peripheral infusion of AngII, only the MnSOD knock-down conﬁned to the SFO, and not the
periphery, demonstrated an increased sensitization and potentiated hypertension. In complementary experi-
ments, over-expressing MnSOD in the SFO signiﬁcantly decreased blood pressure in response to chronic AngII.
Overall, these studies indicate that mitochondrial O2
•− in the brain SFO works in concert with other AngII-
dependent factors to drive an increase in MAP, as elevated mitochondrial O2
•− alone, either in the SFO or
peripheral tissues, failed to raise baseline blood pressure.
1. Introduction
Reactive oxygen species (ROS) such as superoxide (O2
•−), hydrogen
peroxide (H2O2), and peroxynitrite (ONOO
-) have been implicated in
the pathogenesis of angiotensin II (AngII)-mediated hypertension
[1,2]. While the downstream reactions of these ROS are distinctly
unique, the derivation of these ROS primarily begins with a one
electron transfer to oxygen forming O2
•−, followed by the dismutation
to H2O2 or the rapid reaction with nitric oxide (NO
•) to form ONOO−
[3]. Thus, the fundamental understanding of how O2
•− is involved in
AngII-mediated hypertension is at the crux of deciphering the redox-
regulation of this disease.
Superoxide may be produced from various subcellular sources in
response to AngII, but mitochondria have been demonstrated to be a
primary source in various cell types [2,4–9]. For example, we have
demonstrated that AngII increases mitochondrial localized O2
•− in
cultured neurons [7,9]. This increase in mitochondrial O2
•− contributes
to the AngII-induced inhibition of outward K+ current as over-
expressing manganese superoxide dismutase (MnSOD), the mitochon-
drial-targeted O2
•− scavenging antioxidant enzyme, attenuates this
AngII-induced neuronal response [7]. Additionally, it has been demon-
strated that over-expression of MnSOD in the subfornical organ (SFO),
a well-established AngII-sensitive cardiovascular control region in the
brain [10,11], in mice attenuates the acute pressor response to
centrally administered AngII [10]. Likewise, whole body over-expres-
sion of MnSOD or systemic infusion of the mitochondrial-targeted
antioxidant MitoTempol has also been shown to attenuate chronic
AngII-mediated hypertension in mice [8]. Conversely, heterozygous
MnSOD mice become more hypertensive compared to wild-type when
aged or challenged with high salt [12]. Overall, these previous studies
are highly suggestive that mitochondrial O2
•− contributes to the
pathogenesis of hypertension; however, it remains unclear if increased
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mitochondrial O2
•− in the absence of pro-hypertensive stimuli is
suﬃcient to increase systemic blood pressure. Further, because whole
body over-expression models of MnSOD or systemic MnSOD hetero-
zygote mice have been utilized, it remains uncertain which cell types or
organs are responsible in mediating changes in blood pressure.
Due to these gaps in knowledge, we set out to examine the tissue-
speciﬁc eﬀects of increased mitochondrial O2
•− on basal and AngII-
challenged hemodynamics. With observations from our lab and others
suggesting mitochondrial O2
•− is a critical signaling molecule in
virtually all cell types, we hypothesized that both central and peripheral
increases in mitochondrial O2
•− elevate baseline systemic MAP, and
moreover sensitize mice to AngII-mediated hypertension. To test this
hypothesis, we utilized a homozygous conditional MnSOD knock-down
mouse (loxP derived; MnSODL/L) combined with two strategies for
targeting cre-recombinase to generate peripheral or brain SFO MnSOD
knock-down animals. While we observed signiﬁcant knock-down of
MnSOD in both models, contrary to our hypothesis, neither model
demonstrated any change in MAP at baseline. However, when chal-
lenged with AngII only the brain SFO MnSOD knock-down animals
displayed a potentiated hypertensive response, thus suggesting mito-
chondrial O2
•− in the SFO plays a preferential role over the periphery in
sensitizing to AngII-mediated hypertension.
2. Materials and methods
2.1. Mice
All experiments were performed using 8–12 week-old male mice of
a C57BL/6 background. Wild-type mice (i.e. C57BL/6NHsd) were
purchased from Harlan Laboratories/Envigo (Indianapolis, IN). Mice
possessing loxP elements ﬂanking (i.e. ﬂoxed) exon 3 of the MnSOD
gene locus (i.e. B6.Cg-Sod2tm1Lox; shorthand MnSODL/L) have been
previously described [13]. Mice possessing a conditionally-expressed
tamoxifen-inducible cre-recombinase targeted to the ubiquitously
expressed ROSA26 gene locus (i.e. B6.129-Gt(ROSA)26Sortm1(cre/
ERT2)Tyj/J; shorthand ROSA-Cre+/+) have been previously described
and were purchased from Jackson Laboratories (Bar Harbor, ME) [14].
MnSODL/L and ROSA-Cre+/+ mice were backcrossed to the F3 genera-
tion to allow for 100% usable progeny of either MnSODL/L ROSA-Cre+/
− (inducible knock-down) or MnSODL/L ROSA-Cre−/− (control) geno-
types. Mice were given access to standard chow (Teklad Laboratory
Diet #7012, Harlan Laboratories, Madison, WI) and water ad libitum.
For all survival surgical procedures, mice were anesthetized using 0.5–
2% isoﬂurane supplemented with 1 l/min oxygen. Bupivacaine (0.5%
solution) was used as post-surgical anesthetic, and mice were mon-
itored daily post-operation for signs of illness or infection. Mice were
euthanized by pentobarbital overdose (150 mg/kg, Fatal Plus, Vortech
Pharmaceuticals, Dearborn, MI) administered intraperitoneally. All
procedures were reviewed and approved by the University of Nebraska
Medical Center Institutional Animal Care and Use Committee.
2.2. Knock-down and over-expression of MnSOD
Protocol 1: For peripheral knock-down of MnSOD, MnSODL/L
ROSA-Cre+/− and −/− mice were treated daily with tamoxifen (Sigma-
Aldrich #T5648, St. Louis, MO) for 5 days. Tamoxifen was resuspended
at 20 mg/mL in sunﬂower seed oil (Sigma-Aldrich #S5007, St. Louis,
MO) and injected at 150 mg/kg intraperitoneally per mouse per day.
While the ROSA26 promoter is expressed in all cell types, negligible
central nervous recombination has been observed in this model after
tamoxifen administration [15], thus allowing for an eﬃcient peripheral
knock-down of MnSOD. Protocol 2: For knock-down of MnSOD in the
brain SFO, MnSODL/L mice were administered adenovirus (4×107
plague-forming units (PFU)) encoding either cre-recombinase (AdCre;
The University of Iowa Viral Vector Core Facility, Iowa City, IA) or
control adenovirus (AdGFP or AdEmpty, collectively AdControl; The
University of Iowa Viral Vector Core Facility, Iowa City, IA) by a one-
time intracerebroventricular (ICV) injection. Stereotactic coordinates,
as previously described [16], where used for ICV injections. Protocol 3:
For over-expression of MnSOD in the SFO, wild-type mice were
administered adenovirus (4×107 PFU) encoding human MnSOD
(AdMnSOD, ViraQuest Inc., North Liberty, IA) or AdControl by a
one-time ICV injection.
2.3. Mean arterial pressure recording
Induction of hypertension was performed by implantation of
subcutaneous osmotic minipumps (Alzet #1002, Durect Corporation,
Cupertino, CA) delivering AngII (400 ng/kg/min; Sigma #A9525, St.
Louis, MO) until complete emptying of the pumps (approximately 3
weeks) [17]. Telemetric recording of mouse hemodynamics has been
previously described in detail [17]. Brieﬂy, blood pressure recordings
were performed using intra-carotid arterial catheters (PA-C10, Data
Sciences International, Minneapolis, MN) attached to radio telemeters
for direct measurement of mean arterial pressure and heart rate in
conscious unrestrained animals. Hemodynamic recordings were per-
formed for 20 s every minute for the same 2-h time period daily for the
duration of the experiment. Averages of mean arterial pressure were
calculated daily over the 2-h period when the mice displayed minimal
activity.
2.4. Tissue isolation
Analysis of tissues for knock-down studies occurred 14 days after
gene recombination (i.e. 14 days after the last tamoxifen injection for
peripheral tissues or virus administration for SFO) to allow endogen-
ous MnSOD protein to degrade, while tissue analysis in over-expres-
sion studies was undertaken 4 days after AdMnSOD injection to allow
production of exogenous MnSOD protein. At time of euthanasia, blood
was removed from the tissues by 0.9% saline solution perfused via
peristaltic pump through the left ventricle of the heart. Following saline
perfusion, tissues were either isolated for use in assays requiring live
cells or further perfused using a 4% paraformaldehyde solution to ﬁx
tissues prior to isolation and analysis.
2.5. Laser-capture microdissection and quantitative reverse
transcription real-time PCR (qRT-PCR)
Freshly isolated and non-ﬁxed brains were snap frozen using dry ice
and mounted in blocks using OCT freeze media (Thermo Fisher
Scientiﬁc #23-730-571, Waltham, MA). Brains were cut by cryostat
to the level of the SFO and 50 μm sections were placed upon RNase-
free frame-foiled polyethylene terephthalate slides (North Central
Instruments #11505190, Plymouth, MN). The SFO region was imaged,
mapped, and dissected on a Leica LMD7000 laser microdissection
microscope. Collected tissue was immediately placed into TRIzol
Reagent (Thermo Fisher Scientiﬁc #15596-018, Waltham, MA), and
total RNA was extracted via manufacturer's instructions. Concentration
of RNA was determined spectrophotometrically using a Nanodrop
2000 Spectrophotometer (Thermo Fisher Scientiﬁc, Waltham, MA),
and cDNA was obtained using the high capacity cDNA archive kit
(Applied Biosystems #4368813, Grand Island, NY). SYBR green qRT-
PCR for MnSOD was performed on a BioRad iCycler iQ Real-Time PCR
Detection System (BioRad, Hercules, California). A threshold in the
linear range of PCR ampliﬁcation was selected and the cycle threshold
(Ct) determined. Levels of transcripts were then normalized to the 18S
loading control and compared relative to the control sample using the
2−ΔΔCt method. Primers speciﬁc to the coding region of either mouse or
human MnSOD were used. Primer sequences were as follows: 18S
forward, 5′-GCCCGAAGCGTTTACTTTGA-3′; 18S reverse, 5′-
TCATGGCCTCAGTTCCGAA-3′; mouse MnSOD forward, 5′-
GCTCTGGCCAAGGGAGATGT-3′; mouse MnSOD reverse, 5′-
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GGGCTCAGGTTTGTCCAGAAA-3′; human MnSOD forward, 5′-
GGCCTACGTGAACAACCTGAA-3′; human MnSOD reverse, 5′-
CTGTAACATCTCCCTTGGCCA-3′.
2.6. Western blotting
Immunoblotting was carried out as previously described [18].
Brieﬂy, freshly perfused non-ﬁxed tissues were sonicated in buﬀered
solution containing protease inhibitors (Sigma #P8340, St. Louis, MO).
After separation by polyacrylamide gel electrophoresis and transfer to
nitrocellulose, membranes were incubated with a 1:1000 dilution one
of the following primary antibodies: CuZnSOD (Santa Cruz
Biotechnology, CA); MnSOD (Upstate Biotech/Millipore, Billerica,
MA) or β-Actin (Sigma, St. Louis, MO). After appropriate secondary
antibody staining and washout, images of membranes were acquired by
a UVP Bioimaging System (UVP LLC, Upland, CA). All three primary
antibodies were utilized on the same membrane by stripping (Thermo
Fisher Scientiﬁc #21059, Waltham, MA) and re-probing to control for
appropriate loading of samples (see Supplementary Fig. 1 for repre-
sentative uncropped image of complete western blot).
2.7. Immunoﬂuorescence
Fixed brain sections were subjected to standard immunoﬂuores-
cence as previously described [9]. Brieﬂy, brains were sectioned by
cryostat at 20 μm to expose the SFO. Sections were permeabilized and
incubated with MnSOD primary antibody (1:200 dilution, Upstate
Biotech/Millipore, Billerica, MA) followed by an Alexa Fluor 594
secondary antibody (1:200, anti-rabbit, Invitrogen, Carlsbad, CA).
Fluorescent images were acquired with a Zeiss 510 Meta Confocal
Laser Scanning Microscope using settings appropriate for GFP and
Alexa Fluor 594.
2.8. Superoxide analysis
Freshly isolated, frozen, and non-ﬁxed brains were sectioned by
cryostat at 20 μm to expose the SFO. Sections were incubated with
10 μM fresh non-oxidized dihydroethidium (DHE; VWR #101447-534,
Chicago, IL) or MitoSOX Red (Thermo Fisher Scientiﬁc #M36008,
Waltham, MA) for 30 min at 37 °C. Solution containing DHE or
MitoSOX was removed, and slides were imaged on a Zeiss 510 Meta
Confocal Laser Scanning Microscope (excitation 488 nm, emission
600 nm). Fluorescence intensity was quantiﬁed utilizing ZEN 2010 B
SP1 and Image J software.
2.9. Statistics
Data are presented as mean ± standard error of the mean (SEM).
Assessments of blood pressure were performed using 2-way ANOVA
followed by Bonferroni correction post hoc test. For two group
comparisons, Student's t-test was used. GraphPad Prism 5.0 statistical
and graphing software was used for all analyses. Diﬀerences were
considered signiﬁcant at p < 0.05.
Fig. 1. MnSOD is only knocked-down in peripheral tissues of the ROSA-Cre tamoxifen inducible mouse model.Mice were treated with tamoxifen (150 mg/kg) daily for
6 days followed by a 14-d incubation period to allow endogenous MnSOD to turnover prior to tissue harvest. A. Representative western blots and quantiﬁcation of MnSOD protein in
various peripheral tissues. B. Representative western blots and quantiﬁcation of MnSOD protein in regions of the brain. C. Schematic of experimental setup and timeline. *p < 0.05 vs.
MnSODL/L ROSA-Cre−/−.
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3. Results
3.1. Peripheral knock-down of MnSOD does not aﬀect blood pressure
response to AngII
To generate a model of peripherally increased mitochondrial O2
•−,
we bred a conditional MnSOD knock-down mouse (MnSODL/L) to a
mouse expressing a tamoxifen-inducible cre-recombinase under the
ubiquitous ROSA26 promoter (ROSA-Cre+/−). While the ROSA26
promoter is expressed in all cell types, minimal central nervous
recombination has been observed in this model after tamoxifen
administration [15], thus allowing for an eﬃcient peripheral knock-
down of MnSOD. This methodology to create a temporally and
spatially-controlled knock-down was utilized due to the embryonic
knock-out of MnSOD being lethal shortly after birth, and thus not
allowing for adult animals to be studied [19,20].
We ﬁrst set out to characterize the eﬃciency of MnSOD knock-
down in our conditional peripheral MnSOD knock-down mice
(MnSODL/L ROSA-Cre+/−). After tamoxifen administration (Fig. 1C),
tissues were harvested for MnSOD protein analysis. Peripheral tissues
demonstrated robust and signiﬁcant knock-down of MnSOD (Fig. 1A);
however, none of the brain regions examined showed any appreciable
change in MnSOD protein levels (Fig. 1B). These data conﬁrm the
observation that the MnSODL/L ROSA-Cre+/−mice accurately reﬂects a
mouse model of peripheral MnSOD knock-down, as opposed to a
complete whole-body knock-down. Furthermore, no change in the
cytoplasmic form of SOD (i.e. copper/zinc SOD, CuZnSOD) was
observed in the MnSODL/L ROSA-Cre+/− mice suggesting the knock-
down of MnSOD in peripheral tissues is speciﬁc and not counteracted
by a compensatory O2
•− removal mechanism (Fig. S2).
Next, to address our hypothesis that knock-down of MnSOD leads
to elevated blood pressure, we measured hemodynamics in the
MnSODL/L ROSA-Cre+/− mice by radiotelemetry. In contrast to our
original hypothesis, we observed no change in baseline mean arterial
pressure (MAP) at any time point after knock-down of MnSOD (Fig. 2).
Moreover, the AngII-induced increase in MAP was not signiﬁcantly
diﬀerent between MnSODL/L ROSA-Cre−/− and MnSODL/L ROSA-
Cre+/− (Fig. 2). Taken together, these unexpected results indicate that
knock-down of MnSOD in peripheral tissues is not suﬃcient to alter
MAP in the presence or absence of AngII.
3.2. Increased mitochondrial superoxide in the brain sensitizes mice
to AngII
Due to the observation that the MnSODL/L ROSA-Cre+/− mice did
not elicit any change in MnSOD protein in the brain, we pursued the
development of a mouse possessing MnSOD knock-down targeted to
the brain SFO; a blood-brain barrier deﬁcient cardiovascular control
nuclei known to be sensitive to circulating AngII [21,22]. To achieve
this, we localized cre-recombinase delivery via intracerebroventricular
(ICV) injection of adenovirus (AdCre or AdControl) in the parental
MnSODL/L mice (Fig. 3A).
To characterize the knock-down of MnSOD in the SFO, we utilized
laser-capture microdissection to speciﬁcally isolate this unique and
diminutive brain region. Quantitative real-time PCR analysis demon-
strated an approximate 60% decrease in MnSOD mRNA in the SFO 14
days after AdCre administration (Fig. 3B). We next examined if the loss
of MnSOD conﬁned to a speciﬁc cardiovascular control region in the
brain would be suﬃcient to alter peripheral MAP. Interestingly, 14
days after the delivery of AdCre (at which point MnSOD expression is
decreased, Fig. 3B), no change in baseline MAP was observed
compared to mice ICV-treated with AdControl (Fig. 3C). However,
peripheral infusion of AngII elicited a signiﬁcantly greater response in
AdCre-treated animals compared to AdControl, suggesting the loss of
MnSOD in the SFO sensitizes mice to AngII hypertension (Fig. 3C). In
congruence with this, once the AngII minipumps emptied (~18 days
after the start of AngII infusion), MAP in both AdCre and AdControl
mice returned to baseline with no signiﬁcant diﬀerences noted
(Fig. 3C).
Next, we examined the O2
•− levels in the SFO during the AngII
infusion time course. After only 2 days of AngII infusion (point at
which the hemodynamics remain signiﬁcantly diﬀerent from control
throughout the infusion) intracellular O2
•− levels were signiﬁcantly
higher in the AdCre treated mice versus AdControl mice infused with
AngII as evidenced by both DHE and MitoSOX oxidation (Fig. 4A and
B). Overall, these data correlate with the observed changes in systemic
hemodynamics and suggest that decreased MnSOD and ampliﬁed
mitochondrial O2
•− speciﬁcally in the SFO of the brain increases the
sensitivity to circulating hypertensive stimuli such as AngII.
3.3. Over-expression of MnSOD in the brain attenuates AngII-
mediated hypertension
With the observation that increased mitochondrial O2
•− in the SFO
increases the AngII hypertensive response, we wanted to examine the
causal role of this ROS in enhancing the response to hypertensive
stimuli. To this end, we developed a model of decreased mitochondrial
O2
•− by over-expressing MnSOD via adenovirus (AdMnSOD) speciﬁ-
cally in the SFO of wild-type mice (Fig. 5A).
Characterization of the SFO from AdMnSOD-injected mice demon-
strated an approximate 70-fold increase in MnSOD mRNA levels
compared to AdControl (Fig. 5B), thus, conﬁrming adenovirus-
mediated gene transfer and enhanced expression of MnSOD.
Adenovirus-mediated transgene expression in the SFO was further
supported by robust immunostaining of both GFP and MnSOD within
the SFO of AdGFP- (AdControl) and AdMnSOD-injected mice, respec-
tively (Fig. 5C).
As previously observed in the other models of MnSOD perturba-
tion, over-expression of MnSOD in the SFO has no impact on baseline
MAP (Fig. 5D). In contrast, peripheral infusion of AngII signiﬁcantly
increased MAP in AdControl mice, but failed to elicit the complete
hypertensive response in mice over-expressing MnSOD in the SFO
Fig. 2. Peripheral MnSOD knock-down does not aﬀect baseline or AngII-
mediated changes in MAP. Mice were treated with tamoxifen (150 mg/kg) daily for 6
days followed by a 14-d incubation period to allow endogenous MnSOD to turnover prior
to subcutaneous AngII infusion (400 ng/kg/min). Daily averages of telemetric MAP data
acquired over the course of the experiment. Tam indicates ﬁnal day of tamoxifen
administration. 2-way ANOVA followed by Bonferroni correction post hoc test was
utilized for statistical analysis.
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(Fig. 5D). Additionally, after AngII had dissipated from the mini-
pumps, no signiﬁcant diﬀerences in MAP were noted in either animal
model (Fig. 5D). Additionally, in response to AngII, O2
•− levels
measured by DHE and MitoSOX ﬂuorescence were attenuated in
AdMnSOD-treated mice versus AdControl (Fig. 6A and B). In sum-
mary, the attenuation of mitochondrial O2
•− in the brain SFO via over-
expression of MnSOD desensitizes mice to chronic, peripheral AngII
challenge.
4. Discussion
The present study elucidated two major ﬁndings. First, knock-down
of MnSOD, the mitochondrial-localized O2
•− scavenging enzyme, in
peripheral tissues or the brain SFO is not suﬃcient to alter MAP under
basal conditions, and second, perturbations of mitochondrial O2
•− in
the SFO, but not peripheral organs, sensitize mice to AngII-dependent
hypertension. While increases in mitochondrial O2
•− have been ob-
served in various cell types in response to AngII [2,7–9,23–25], these
ﬁndings raise the question if certain cell types and/or organs are more
dependent upon this mitochondrial-localized ROS than others when
perpetuating the AngII signaling cascade.
Previous studies have demonstrated that AngII increases mitochon-
drial O2
•− in neurons and that over-expression of MnSOD is able to
reverse AngII-mediated responses in these cells suggesting a causal
role for mitochondrial O2
•− in mediating AngII intraneuronal signaling
[4–7,9]. Interestingly, we have shown that over-expression of copper
zinc superoxide dismutase (CuZnSOD), which is traditionally charac-
terized as being localized to cytoplasm, also reverses the AngII-
mediated eﬀects on neurons [18]. While this may suggest a non-
mitochondrial source of AngII-derived O2
•−, numerous studies have
reported that CuZnSOD is expressed in the intramitochondrial mem-
brane space (IMM) [26–29]. We have found that adenovirus-mediated
over-expression of CuZnSOD in neurons leads to an accumulation of
the enzyme in mitochondria, thus further supporting the idea that this
enzyme plays a role in attenuating mitochondrial O2
•− in response to
AngII [18]. In addition to our work, others have also observed
mitochondrial O2
•− as a primary signaling molecule in AngII-mediated
hypertension models. For example, vascular endothelial cells have
demonstrated an increase in mitochondrial O2
•− in response to AngII
[2,8,23]. This increase in mitochondrial O2
•− led to a dysfunctional
vascular tone, disruption of mitochondrial metabolism, and an increase
in MAP that could be reversed by the systemic administration of
MitoTempol, a mitochondrial-targeted O2
•− scavenger. Overall, these
data together suggest a strong role for O2
•− derived in the mitochondria
Fig. 3. MnSOD knock-down in the SFO sensitizes mice to chronic AngII-mediated hypertension. Mice were treated with a one-time ICV injection of either AdCre or
AdControl virus followed by a 14-d incubation period to allow endogenous MnSOD to turnover prior to tissue harvest. A. Schematic of experimental setup and timeline. B. Quantitative
real-time RT-PCR analysis of MnSOD mRNA from SFO tissue obtained via laser microdissection. *p < 0.05 vs. AdControl. C. Daily averages of telemetric MAP data acquired over the
course of the experiment. 2-way ANOVA followed by Bonferroni correction post hoc test was utilized for statistical analysis.
A.J. Case et al. Redox Biology 11 (2017) 82–90
86
in driving AngII-mediated hypertension. However, our work presented
here suggests that increasing mitochondrial O2
•− in the absence of
AngII is not suﬃcient to increase MAP, which implies multiple
mechanisms in addition to mitochondrial redox regulation are most
likely at play in regards to AngII-dependent hypertension.
One possible explanation for why increased mitochondrial O2
•− is
not suﬃcient to increase MAP may be due to the directionality of the
O2
•− produced in response to AngII. As previously mentioned, we have
shown that over-expression of CuZnSOD is able to attenuate mito-
chondrial derived O2
•− in response to AngII, and thus has a rescuing
eﬀect in neurons [18]. This would suggest that the mitochondrial O2
•−
that mitigates the eﬀects of AngII may be primarily the O2
•− produced
into the IMM space of the mitochondria as opposed to the matrix. Our
study presented herein utilized mouse models possessing increased
steady-state O2
•− in the mitochondrial matrix due to the knock-down of
MnSOD, and thus this spatial diﬀerence in ROS production may lead to
diﬀerential regulatory control of cellular processes. However, this
theory is convoluted by the numerous observations that MnSOD
over-expression, and thus lowering of mitochondrial matrix O2
•−,
may also attenuate AngII-mediated signaling [7,8,10]. Another possi-
ble explanation may be that in addition to increasing mitochondrial-
localized O2
•−, AngII recruits redox-regulated proteins necessary for
signal transduction in close proximity to the mitochondria. We have
shown that Ca2+/calmodulin kinase II (CaMKII), a known redox-
regulated enzyme [30], becomes activated in response to AngII and
this activation is reversed by the over-expression of MnSOD [7]. Others
have demonstrated that the enzyme protein kinase C (PKC) also
contributes to AngII signaling [2], therefore increasing the number of
potential redox-sensitive components that may be interacting with
AngII-mediated mitochondrial O2
•−. Thus, simply increasing mito-
chondrial O2
•− (via MnSOD knock-down) without altering the activity
of these signaling proteins would not reproduce the same eﬀect elicited
by AngII stimulation, and may explain why baseline hemodynamics
were not aﬀected in any of our mouse models.
Another possible reason increased mitochondrial O2
•− alone did not
change baseline blood pressure may be due to the regions in which the
MnSOD knock-down was targeted. It has been previously observed that
increased mitochondrial O2
•− in the rostral ventrolateral medulla
(RVLM), another cardiovascular control region in the brain, increases
systemic blood pressure [4–6]. In spontaneous hypertensive rats
(SHR), these animals have been shown to possess decreased expression
of MnSOD and increased mitochondrial O2
•− speciﬁcally in the RVLM
of the brain [5]. This increase in mitochondrial O2
•− appeared partially
causal to the phenotypic hypertension as over-expression of MnSOD
speciﬁcally in the RVLM was able to lower systemic mean arterial
pressure in these animals [5]. Moreover, administration of the
mitochondrial complex I inhibitor rotenone, which further increases
mitochondrial O2
•−, to the RVLM was able to potentiate the systemic
hypertension in these animals [5]. The brain RVLM is a primary
integration site in the brain stem regulating sympathetic outﬂow [31],
thus perturbations of mitochondrial O2
•− in the RVLM may aﬀect
sympathetic drive, which would have signiﬁcant impacts on peripheral
Fig. 4. MnSOD knock-down in the SFO mice elevates mitochondrial O2
•− in response to systemic AngII infusion. Mice were treated with a one-time ICV injection of
either AdCre or AdControl virus followed by a 14-d incubation period to allow endogenous MnSOD to turnover prior to subcutaneous AngII infusion (400 ng/kg/min). Tissue was
isolated 2 days following AngII infusion. A. Left, representative confocal microscopy images showing DHE ﬂuorescence in the brain SFO from an AdControl or AdCre-injected mouse
with or without AngII infusion. Right, quantiﬁcation of DHE oxidation. B. Left, representative confocal microscopy images showing MitoSOX ﬂuorescence in the brain SFO from an
AdControl or AdCre-injected mouse with or without AngII infusion. Right, quantiﬁcation of MitoSOX oxidation. 2-way ANOVA followed by Bonferroni correction post hoc test was
utilized for statistical analysis. Scale bar=100 μm.
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vascular tone and blood pressure regulation. In the work presented
herein, knock-down of MnSOD in the brain was primarily conﬁned to
the SFO. The SFO does not directly project to the RVLM [32], and as
such may explain why increases in mitochondrial O2
•− in the SFO in the
absence of hypertensive stimuli may not elicit the same hemodynamic
phenotype.
While we discovered that increased mitochondrial O2
•− alone did
not aﬀect baseline blood pressure in our animals, we did observe that
increases in central mitochondrial O2
•−, particularly in the brain SFO,
did in fact sensitize the mice to AngII-mediated hypertension. This may
be due to inherent cell type-speciﬁc diﬀerences in AngII-signaling. For
example, we have recently observed that a source of mitochondrial O2
•−
in AngII-stimulated neurons is NADPH oxidase 4 (NOX4) [9]. We
observed that NOX4 is partially localized to the mitochondria, and that
Fig. 5. Over-expression of MnSOD in the SFO decreases peripheral blood pressure in response to chronic AngII-mediated infusion. Mice were treated with a one-
time ICV injection of either AdMnSOD or AdControl virus followed by a 4-d incubation period to allow exogenous MnSOD to be expressed prior to tissue harvest. A. Schematic of
experimental setup and timeline. B. Quantitative real-time RT-PCR analysis of MnSOD mRNA from SFO tissue obtained via laser microdissection. *p < 0.05 vs. AdControl. C.
Representative confocal microscopy images of GFP and MnSOD protein expression in the brain SFO from an AdControl (GFP) or AdMnSOD-injected mouse. D. Daily averages of
telemetric MAP data acquired over the course of the experiment. 2-way ANOVA followed by Bonferroni correction post hoc test was utilized for statistical analysis. Scale bar=100 μm.
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siRNA down-regulation of NOX4 attenuates AngII-mediated mito-
chondrial O2
•− production in cultured neurons [9]. In contrast, in
endothelial cells NOX4 appears not to be localized to mitochondria,
and moreover, NOX2 was demonstrated to be a primary contributor to
the generation of mitochondrial O2
•− [23]. These cell type speciﬁc
nuances may partially explain why the loss of MnSOD in the central
nervous system and not peripheral tissues sensitizes mice to AngII.
Another potential explanation for the central versus peripheral dis-
crepancy may be due to cellular function. We have previously shown
that AngII-mediated mitochondrial O2
•− inhibits neuronal potassium
current [7], and thus increases neuronal ﬁring. It may be possible that
the loss of MnSOD and ensuing increase in mitochondrial O2
•− has a
similar eﬀect on neurons located in the SFO, and that the addition of
AngII further exacerbates this eﬀect leading to potentiated neuronal
ﬁring. Due to SFO neurons playing a major role in the regulation of
cardiovascular function [21,32,33], this may explain why systemic
MAP increases are exaggerated in response to AngII only in the SFO
knock-down of MnSOD. In contrast, knock-down of MnSOD and
increases in mitochondrial O2
•− in peripheral tissues may not inﬂuence
central neuronal ﬁring, and as such are not suﬃcient to sensitize to
AngII-induced systemic hemodynamic changes.
5. Conclusions
Hypertension is a multifactorial disease that is associated with
increases in redox signaling. However, the use of antioxidants in the
amelioration of the disease has proved unsuccessful to date [34]. One
possible explanation for this failure is that the antioxidants currently
utilized do not target the appropriate cell type, subcellular location, or
speciﬁc ROS produced that perpetuates the hypertension. We and
others have shown that mitochondrial O2
•− is a speciﬁc ROS necessary
in the pathogenesis of hypertension [2,8–10,18,23]. While whole body
administration of mitochondria-targeted O2
•− scavengers or over-
expression of MnSOD has proven beneﬁcial in the attenuation of
AngII-mediated experimental hypertension [8], these ﬁndings have not
elucidated the speciﬁc tissues in which these mitochondrial-localized
antioxidants are eliciting their eﬀects. Our work here demonstrates that
increased mitochondrial O2
•− in peripheral tissues or the brain is not
suﬃcient to alter systemic hemodynamics, but increases in mitochon-
drial O2
•− in the brain SFO potentiate AngII-mediated hypertension.
These ﬁndings advance the understanding of the speciﬁcs behind ROS
in elevated blood pressure, and have elucidated a primary organ (i.e.
the brain SFO) and subcellular (i.e. mitochondria) target, as well as a
speciﬁc ROS (i.e. O2
•−) for therapeutic intervention in the treatment of
hypertension associated with elevated levels of AngII.
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